Fontas E, Kousignian I,
Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L,
Levy Y, Costagliola D, on behalf of the FHDH ANRS CO4 ANRS CO14. Interleukine-2 therapy does not increase the risk of Hodgkin or
non-Hodgkin lymphoma in HIV-infected patients; results from FHDH ANRS
CO4. J Acquir Immune Defic Syndr 2009, 50(2):206-14. Lien PubMed
Landman
R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux
G, Bentata M, Brun-Vézinet F, Aboulker JP, and Yéni P, on behalf of the
ANRS 127 study group.Efficacy and safety of ritonavir-boosted
dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected
patients: the 2IP ANRS 127 study. J Antimicrob Chemother 2009, 64:118-125. Lien PubMed
Bouldouyre
MA, Charreau I, Marchou B, Tangre P, Katlama C, Morlat P, Meiffrédy V,
Vittecoq D, Bierling P, Aboulker JP, Molina JM and the ANRS 106 study
group.Incidence and Risk Factors of Thrombocytopenia in
Patients Receiving Intermittent Antiretroviral Therapy: A Sub-study of
the ANRS 106 - Window Trial. JAIDS 2009. Lien PubMed
Ceci A, Giaquinto C, Aboulker JP, Baiardi P, Bonifazi F, Della Pasqua O, Nicolosi A, Taruscio D, Sturkenboom M, Wong I.The Task-force in Europe for Drug Development for the Young (TEDDY) network of excellence. Pediatr Drugs 2009, 11:18-21. Lien PubMed
Molina
JM, Levy Y, Fournier I, Hamonic S, Bentata M, Beck-Wirth G, Gougeon ML,
Venet A, Madelaine I, Sereni D, Jeanblanc F, Boulet T, Simon F,
Aboulker JP; Agence Nationale de Recherches sur le SIDA et les Hépatites
Virales (ANRS) 119 Interstart Study Team.Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis. 2009, 200:206-15. Lien PubMed
De
Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F,
Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I,
Aboulker JP, Molina JM, and the EASIER ANRS 138 study group.Switch
from Enfuvirtide to Raltegravir in Virologically Suppressed
Multidrug-Resistant HIV-1-Infected Patients: A Randomized Open-Label
Trial. Clin Infect Dis. 2009, 49:1259-67. Lien PubMed
Altavilla A, Giaquinto C, Giocanti D, Manfredi C, Aboulker
JP, Bartoloni F, Cattani E, Lo Giudice M, Mellado Peña, Nagler R,
Peterson C, Vajnerova O, Bonifazi F and Ceci A. Activity of ethics committees in Europe on issues related to clinical trials in paediatrics: results of a survey. Pharmaceuticals Policy and Law 2009, 11:79-87.
Lien PubMed
Larrouy L, Chazallon
C, Landman R, Capitant C, Collin, G Storto A, Peytavin G, Pialoux G,
Katlama C, Girard PM, Yeni P, Aboulker JP, Brun-Vezinet F, Descamps D.
Impact
of Gag genetic determinants and gag-pol frameshift stability on
virological response to dual-boosted protease inhibitor combinations in
antiretroviral-naive patients (ANRS 127 trial). Antiviral Ther 2009, 14:A61. Lien PubMed
Insight-Esprit Study
Group, Silcaat Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker
A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane
HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi
G, Wentworth D. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009, 361:1548-59. Lien PubMed
Descamps D, Chazallon C, Loveday C, et al.Resistance
and Virological Response Analyses in a Three Initial Treatment Strategy
Trial: A Substudy of the INITIO Trial. HIV Clin Trials 2009, 10:385-393.Lien PubMed